Seven Fleet Capital Management LP Invests $306,000 in Climb Bio, Inc. $CLYM

Seven Fleet Capital Management LP acquired a new stake in Climb Bio, Inc. (NASDAQ:CLYM) in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 76,400 shares of the company’s stock, valued at approximately $306,000.

Other hedge funds also recently bought and sold shares of the company. Virtu Financial LLC purchased a new position in Climb Bio during the fourth quarter valued at approximately $43,000. XTX Topco Ltd boosted its holdings in Climb Bio by 19.4% in the 4th quarter. XTX Topco Ltd now owns 34,852 shares of the company’s stock valued at $139,000 after purchasing an additional 5,668 shares during the period. Squadron Capital Management LLC bought a new position in Climb Bio in the 4th quarter valued at $400,000. Sphera Funds Management LTD. grew its position in shares of Climb Bio by 114.4% during the 4th quarter. Sphera Funds Management LTD. now owns 932,247 shares of the company’s stock valued at $3,729,000 after purchasing an additional 497,410 shares in the last quarter. Finally, Balyasny Asset Management L.P. purchased a new position in shares of Climb Bio during the 4th quarter valued at $57,000. Hedge funds and other institutional investors own 69.76% of the company’s stock.

Climb Bio Stock Performance

Climb Bio stock opened at $11.45 on Friday. The firm’s fifty day moving average price is $10.33 and its 200-day moving average price is $7.00. The stock has a market cap of $655.63 million, a P/E ratio of -14.68 and a beta of 0.09. Climb Bio, Inc. has a fifty-two week low of $1.17 and a fifty-two week high of $12.48.

Climb Bio (NASDAQ:CLYM) last announced its earnings results on Thursday, May 7th. The company reported ($0.20) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.26) by $0.06. On average, analysts predict that Climb Bio, Inc. will post -0.87 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on CLYM shares. Oppenheimer increased their price objective on Climb Bio from $10.00 to $18.00 and gave the stock an “outperform” rating in a research report on Tuesday, April 21st. Weiss Ratings restated a “sell (d-)” rating on shares of Climb Bio in a research report on Monday, April 20th. B. Riley Financial started coverage on Climb Bio in a research note on Tuesday, March 24th. They issued a “buy” rating and a $26.00 target price on the stock. BTIG Research raised their price target on Climb Bio from $19.00 to $20.00 and gave the company a “buy” rating in a report on Thursday, June 11th. Finally, Raymond James Financial started coverage on Climb Bio in a research report on Tuesday, March 10th. They set a “strong-buy” rating and a $25.00 price target for the company. Three research analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $21.73.

Climb Bio Profile

Climb Bio Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered protein therapeutics for the treatment of cancer and immune-mediated disorders. The company’s mission centers on designing biologics with enhanced specificity and functional activity to engage key cellular targets and improve patient outcomes in areas of high unmet need.

At the heart of Climb Bio’s approach is its proprietary protein engineering platform, which combines mammalian cell display, directed evolution and computational modeling.